◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CLDX

Celldex Therapeutics Inc (CLDX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-29

Celldex Therapeutics Inc (CLDX) operates in the BIOTECHNOLOGY industry and is headquartered in Hampton, United States with about 198 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, CLDX reported $2M in revenue and ($259M) in net income.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

Interactive charts & full statements → Open the CLDX valuation workbench →

CLDX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$2M	$7M	$7M	$2M	$5M	$7M	$4M	$10M	$13M	$7M	$5M	$4M	$4M	$11M	$9M	$47M	$15M	$7M	$5M	$5M
Gross Profit	($64M)	$2M	($157M)	($111M)	($80M)	($49M)	($35M)	($39M)	($57M)	($83M)	($95M)	$1M	$0M	$2M	$0M	$0M	$35M	$7M	$7M	$5M	$5M
Gross Margin %	—	100.0%	-2229.8%	-1614.5%	-3389.9%	-1046.2%	-473.4%	-1094.3%	-596.7%	-654.7%	-1403.5%	26.8%	5.2%	43.2%	3.8%	1.6%	74.2%	44.7%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($326M)	($287M)	($195M)	($155M)	($115M)	($71M)	($63M)	($55M)	($156M)	($122M)	($133M)	($130M)	($122M)	($81M)	($58M)	($43M)	($6M)	($33M)	($34M)	($23M)	($22M)
Operating Margin %	—	-19160.0%	-2778.9%	-2245.3%	-4889.0%	-1531.8%	-854.1%	-1540.2%	-1640.1%	-953.7%	-1958.7%	-2363.9%	-3414.1%	-1981.1%	-518.5%	-468.4%	-13.8%	-216.4%	-456.0%	-447.9%	-453.6%
Net Income	($301M)	($259M)	($158M)	($141M)	($112M)	($71M)	($60M)	($51M)	($151M)	($93M)	($129M)	($127M)	($118M)	($82M)	($59M)	($45M)	($3M)	($37M)	($48M)	($22M)	($20M)
Net Margin %	—	-17253.3%	-2248.8%	-2054.8%	-4765.6%	-1516.0%	-805.9%	-1424.0%	-1585.1%	-730.1%	-1894.0%	-2321.1%	-3292.8%	-1983.7%	-527.8%	-483.5%	-5.4%	-240.6%	-637.1%	-424.1%	-413.2%
EBITDA	($298M)	($255M)	($155M)	($139M)	($104M)	($66M)	($46M)	($50M)	($73M)	($104M)	($124M)	($126M)	($115M)	($78M)	($54M)	($39M)	$5M	($33M)	($45M)	($19M)	($18M)
Earnings Per Share (EPS)	$-4.35	$-3.89	$-2.45	$-2.92	$-2.40	$-1.64	$-2.02	$-3.51	$-14.48	$-10.86	$-18.99	$-19.66	$-19.81	$-15.33	$-15.37	$-17.01	$-1.19	$-27.64	$-50.12	$-22.00	$-49.41
Shares Outstanding (M)	78M	66M	64M	48M	47M	43M	30M	15M	10M	9M	7M	6M	6M	5M	4M	3M	2M	1M	1M	1M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CLDX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$1M	$1M	$1M	$3M
Gross Profit	$0M	($1M)	$0M	($63M)	($53M)	($52M)	$0M	($42M)
Gross Margin %	100.0%	-5593.3%	100.0%	—	-7324.1%	-7470.4%	30.3%	-1318.5%
Operating Income (EBIT)	($81M)	($84M)	($87M)	($74M)	($64M)	($63M)	($56M)	($52M)
Operating Margin %	-366468.2%	-562900.0%	-116249.3%	—	-8747.5%	-9027.2%	-4768.3%	-1633.5%
Net Income	($74M)	($79M)	($81M)	($67M)	($57M)	($54M)	($47M)	($42M)
Net Margin %	-334104.6%	-524566.7%	-108480.0%	—	-7753.4%	-7740.4%	-4007.8%	-1320.0%
EBITDA	($73M)	($78M)	($81M)	($66M)	($56M)	($53M)	($46M)	($41M)
Earnings Per Share (EPS)	$-0.94	$-1.18	$-1.22	$-1.01	$-0.85	$-0.81	$-0.71	$-0.64
Shares Outstanding (M)	78M	67M	66M	66M	66M	66M	66M	66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CLDX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($236M)	($211M)	($158M)	($107M)	($104M)	($61M)	($40M)	($46M)	($75M)	($100M)	($113M)	($99M)	($102M)	($68M)	($50M)	($36M)	($30M)	($30M)	$18M	($19M)	$27M
Capital Expenditures (CapEx)	$6M	$3M	$2M	$2M	$2M	$1M	$2M	$1M	$1M	$2M	$3M	$5M	$2M	$4M	$0M	$1M	$2M	$1M	$1M	$5M	$9M
Free Cash Flow (FCF)	($242M)	($214M)	($160M)	($109M)	($106M)	($62M)	($42M)	($47M)	($76M)	($102M)	($116M)	($104M)	($103M)	($72M)	($50M)	($36M)	($32M)	($30M)	$17M	($24M)	$18M
FCF Margin %	—	-14243.9%	-2274.9%	-1585.2%	-4478.6%	-1336.4%	-565.6%	-1319.5%	-797.3%	-798.2%	-1706.3%	-1893.5%	-2885.3%	-1748.7%	-447.1%	-390.4%	-69.4%	-200.2%	227.7%	-475.8%	358.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CLDX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($57M)	($66M)	($64M)	($49M)	($44M)	($54M)	($32M)	($55M)
Capital Expenditures (CapEx)	$3M	$2M	$1M	$0M	$1M	$0M	$1M	$1M
Free Cash Flow (FCF)	($61M)	($67M)	($65M)	($49M)	($45M)	($55M)	($33M)	($56M)
FCF Margin %	-275404.6%	-448180.0%	-86577.3%	—	-6127.8%	-7861.4%	-2828.3%	-1753.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CLDX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$782M	$583M	$792M	$466M	$353M	$445M	$236M	$123M	$156M	$316M	$383M	$338M	$248M	$347M	$126M	$98M	$110M	$140M	$70M	$38M	$61M
Cash & Cash Equivalents	$47M	$29M	$28M	$35M	$29M	$39M	$44M	$11M	$24M	$40M	$42M	$72M	$28M	$169M	$25M	$12M	$21M	$57M	$44M	$16M	$41M
Total Liabilities	$68M	$56M	$45M	$36M	$27M	$25M	$26M	$29M	$32M	$79M	$118M	$47M	$36M	$27M	$30M	$29M	$35M	$67M	$52M	$57M	$59M
Total Debt (Short + Long-Term)	$2M	$2M	$1M	$2M	$1M	$2M	$1M	$4M	$5M	$7M	$5M	$4M	$3M	$0M	$11M	$15M	$24M	$14M	$1M	$2M	$0M
Total Shareholders' Equity	$715M	$527M	$747M	$429M	$326M	$419M	$209M	$94M	$124M	$236M	$265M	$290M	$212M	$320M	$96M	$69M	$75M	$74M	$18M	($19M)	$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CLDX viewer.

Other Companies in BIOTECHNOLOGY

RCUS · Arcus Biosciences Inc — $3 billion
DNLI · Denali Therapeutics Inc — $3 billion
QURE · Uniqure NV — $3 billion
MBX · MBX Biosciences, Inc. Common Stock — $3 billion
ZLAB · Zai Lab Ltd — $3 billion
PGEN · Precigen Inc — $3 billion
ATAI · ATAI Life Sciences BV — $3 billion
IMNM · Immunome Inc — $3 billion

← CLDN All “C” companies CLEAN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.